Dicerna Pharmaceuticals (NASDAQ:DRNA) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.15), Fidelity Earnings reports. Dicerna Pharmaceuticals had a negative net margin of 737.93% and a negative return on equity of 50.30%. The company had revenue of $8.04 million for the quarter, compared to the consensus estimate of $11.70 million.
Shares of NASDAQ DRNA traded up $0.09 during mid-day trading on Friday, reaching $17.69. The company’s stock had a trading volume of 824,800 shares, compared to its average volume of 465,156. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.65. Dicerna Pharmaceuticals has a 52 week low of $9.31 and a 52 week high of $18.39. The firm has a market capitalization of $1.17 billion, a PE ratio of -14.74 and a beta of 2.29. The stock has a fifty day moving average of $15.51 and a two-hundred day moving average of $14.24.
In other Dicerna Pharmaceuticals news, COO James B. Weissman sold 15,000 shares of the company’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $18.00, for a total value of $270,000.00. Following the completion of the transaction, the chief operating officer now owns 29,704 shares in the company, valued at $534,672. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James B. Weissman sold 14,680 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $13.07, for a total transaction of $191,867.60. Following the completion of the transaction, the insider now owns 9,800 shares of the company’s stock, valued at approximately $128,086. The disclosure for this sale can be found here. Insiders sold 42,180 shares of company stock valued at $686,868 in the last 90 days. 21.28% of the stock is currently owned by insiders.
Several research firms have issued reports on DRNA. Chardan Capital reissued a “buy” rating and set a $18.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, August 13th. Leerink Swann boosted their price target on Dicerna Pharmaceuticals from $22.00 to $26.00 in a report on Friday, November 1st. HC Wainwright set a $22.00 price objective on Dicerna Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 26th. Robert W. Baird assumed coverage on Dicerna Pharmaceuticals in a research note on Tuesday, October 29th. They issued an “outperform” rating and a $27.00 price objective for the company. Finally, BidaskClub raised Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $22.50.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Read More: What are CEFs?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.